Home Previous Slide◀︎ Next Slide▶︎ We act with care to create value in the lives of the people we serve We always strive to find new ways to deliver solutions to people living with severe diseases Everyone deserves to live the best life that they can Current Slide Current Slide Current Slide
At UCB, we believe that everyone deserves to live the best life that they can. That’s why - as a global biopharmaceutical leader - we’re focused on creating valuable solutions that improve the lives of people living with neurological and autoimmune conditions. Discover more about us UCBCares® UCBCares® is a personalized service offered by UCB to support people living with a disease and healthcare professionals during their treatment journey with a UCB medicine. Contact us here A home for innovation Innovation is a key driver of progress in every aspect of human life including advancing healthcare. Find out more UCB Stories & Newsroom Story Delivering today, shaping what comes next Read More Story 8 Jul 2026 Seeing beyond the surface: understanding the impact of ocular symptoms in myasthenia gravis Read More Story 3 Jul 2026 FASTRAX working session highlights progress in axSpA diagnosis Read More Press release 30 Jul 2026 UCB Delivers Strong Results, Raises 2026 Guidance and Positions for Next Growth Phase Read More Press release 8 Jul 2026 UCB presents latest data from its targeted generalized myasthenia gravis treatment portfolio at... Read More Empowering women of childbearing age Discover the Unbearable Home “Every breakthrough we achieve brings us closer to a world where patients can live better, healthier lives.” Sustainability Sustainability is at the heart of everything we do at UCB, guiding our decisions to positively impact society, support communities, and protect the planet for future generations. Learn more UCB ventures UCB Ventures invests in pioneering companies and technologies that have the potential to transform the lives of people living with severe diseases. Learn more
Story 8 Jul 2026 Seeing beyond the surface: understanding the impact of ocular symptoms in myasthenia gravis Read More
Press release 30 Jul 2026 UCB Delivers Strong Results, Raises 2026 Guidance and Positions for Next Growth Phase Read More
Press release 8 Jul 2026 UCB presents latest data from its targeted generalized myasthenia gravis treatment portfolio at... Read More